Eculizumab: Another breakthrough

Research output: Contribution to journalComment/debatepeer-review

Abstract

In this issue of Blood, Harder et al demonstrate that breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab is due to strong activation of the complement cascade, leading to higher C3b density, which may cause a conformation change limiting the ability of eculizumab to block terminal complement.1

Original languageEnglish (US)
Pages (from-to)922-923
Number of pages2
JournalBlood
Volume129
Issue number8
DOIs
StatePublished - Feb 23 2017

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Eculizumab: Another breakthrough'. Together they form a unique fingerprint.

Cite this